GLP-1 weight-loss boom risks diverting pharma focus from insulin supply, warns foundation

The Access to Medicine Foundation warns that the commercial gold rush into GLP-1 weight-loss drugs may divert pharmaceutical firms' attention and resources away from essential diabetes treatments like insulin, exacerbating access gaps in poorer countries. The report highlights a shift in corporate focus toward high-margin weight-loss markets, potentially undermining basic diabetes care. The claim is based on an advocacy group's analysis, not yet corroborated by independent data, but signals a structural risk to global insulin supply chains.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works